BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 8683314)

  • 41. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
    Martoni AA; Zamagni C; Quercia S; Rosati M; Cacciari N; Bernardi A; Musto A; Fanti S; Santini D; Taffurelli M
    Cancer; 2010 Feb; 116(4):805-13. PubMed ID: 20052718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
    Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
    Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Herrada J; Iyer RB; Atkinson EN; Sneige N; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 1997 Sep; 3(9):1565-9. PubMed ID: 9815844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
    Nieweg OE; Kim EE; Wong WH; Broussard WF; Singletary SE; Hortobagyi GN; Tilbury RS
    Cancer; 1993 Jun; 71(12):3920-5. PubMed ID: 8389655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The value of positron emission tomography in the follow-up for breast cancer.
    Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
    Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis.
    Yutani K; Tatsumi M; Shiba E; Kusuoka H; Nishimura T
    J Nucl Med; 1999 Jun; 40(6):1003-8. PubMed ID: 10452318
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
    Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
    J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET.
    Hoshikawa H; Mitani T; Nishiyama Y; Yamamoto Y; Ohkawa M; Mori N
    Auris Nasus Larynx; 2009 Apr; 36(2):192-8. PubMed ID: 18606510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Standard uptake value of 18F-fluorine-2-deoxyglucose is correlated with the expression of estrogen receptor in duct carcinoma of breast].
    Wen GH; Feng YL; Deng HF; Yu FZ; Liu DJ; Yuan JW; He XH; Huang KM; Liu SS; Yang M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):448-50. PubMed ID: 18575338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
    Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
    J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.
    Yanai A; Itoh M; Hirakawa H; Yanai K; Tashiro M; Harada R; Yoshikawa A; Yamamoto S; Ohuchi N; Ishida T
    Tohoku J Exp Med; 2018 May; 245(1):13-19. PubMed ID: 29731479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET.
    Cremerius U; Bares R; Weis J; Sabri O; Mull M; Schröder JM; Gilsbach JM; Buell U
    J Nucl Med; 1997 Jan; 38(1):26-30. PubMed ID: 8998144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
    Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience.
    Rosen EL; Turkington TG; Soo MS; Baker JA; Coleman RE
    Radiology; 2005 Feb; 234(2):527-34. PubMed ID: 15671006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.
    Keune JD; Jeffe DB; Schootman M; Hoffman A; Gillanders WE; Aft RL
    Am J Surg; 2010 Apr; 199(4):477-84. PubMed ID: 20359567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET.
    Gupta NC; Maloof J; Gunel E
    J Nucl Med; 1996 Jun; 37(6):943-8. PubMed ID: 8683316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carbon-11-thymidine and FDG to measure therapy response.
    Shields AF; Mankoff DA; Link JM; Graham MM; Eary JF; Kozawa SM; Zheng M; Lewellen B; Lewellen TK; Grierson JR; Krohn KA
    J Nucl Med; 1998 Oct; 39(10):1757-62. PubMed ID: 9776283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.